HOME >> BIOLOGY >> NEWS
Gene Shears In Cutting Edge Anti-Aids Trial

CSIRO's revolutionary "gene shears" technology has entered clinical trials in adults as the first step in developing a potential treatment for the human immunodeficiency virus (HIV) which causes AIDS, the chief executive of Gene Shears Pty Ltd, Dr Leigh Farrell announced today.

The Phase One clinical trial, conducted at St Vincent's Hospital, Sydney, is testing the safety and ability of Gene Shears' patented gene therapy to inhibit HIV replication in infected patients.

HIV attacks a special class of white blood cell, the CD4+ lymphocyte, which forms the backbone of the human immune defence against attacks by infection. Loss of these white blood cells causes the immune system eventually to break down.

The basis for the trial is the original discovery by CSIRO Plant Industry molecular biologists Dr Jim Haseloff and Dr Wayne Gerlach that naturally-occurring enzymes called ribozymes (dubbed "gene shears") can be used selectively to chop up pieces of genetic material. Gene Shears Pty Ltd went on to prove in laboratory experiments that ribozymesit could be used to prevent the replication of HIV by cutting its genetic material.

The chief executive of CSIRO, Dr Malcolm McIntosh, welcomed news that human trials of the anti-HIV gene shears were under way. "It is extremely pleasing that this fundamental Australian discovery is now starting to bear fruit in the form of practical applications which promise to improve human health and wellbeing," he said.

"It highlights the national importance of CSIRO continuing to perform excellent basic science designed to gain new knowledge."

The Sydney experiment involves six pairs of identical twins, of whom one of each pair is HIV-positive.

CD4+ white blood cells taken from the uninfected twin are equipped with the anti-HIV ribozyme and then infused into the HIV-infected twin.

The trial seeks first to establish that the ribozyme is safe and has no side-effects on the patien
'"/>

Contact: Dr Leigh Farrell
genes@ozemail.com.au
61-2-9878-8200
CSIRO Australia
4-Aug-1997


Page: 1 2

Related biology news :

1. Cutting-edge cancer researchers sought for international recognition
2. Cutting back on cigarettes: when less is more
3. AChemS: Cutting edge research in taste, smell, & chemical irritation
4. Cutting edge
5. Cutting-edge research to be presented at ASCPT pharmacology conference
6. Cutting the risk of coronary disease - start before birth says UK doctor
7. Story Tips: Engineering Students Pursue Cutting-Edge Research
8. Brain Building May Depend On DNA Cutting And Pasting
9. Cutting The Time And Cost Of Developing New Cures: Lord Sainsbury Launches Worlds First Biomedical Accelerator Mass Spectrometer In York
10. Flexibility In Cutting Toxic Releases Yields Dividends
11. Trial shows which brain cancer patients benefit from temozolomide

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Gene Shears Cutting Edge Anti Aids Trial

(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
(Date:3/20/2015)... -- NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or ... growing mobile commerce market, announces its biometric payment technology, ... featured in 2015 "I Want That" International CES Special, ... the DIY Network.   DIY,s "I Want ... site of the 2015 International CES for a firsthand ...
(Date:3/17/2015)... , March 17, 2015 ... company specializing in clinical study management systems, is ... in attendance at ARENA,s Outsourcing in Clinical Trials ... This event provides an excellent forum for MedNet ... flexible and affordable software-as-a-service (SaaS) eClinical technology platform. ...
Breaking Biology News(10 mins):Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 2NXT-ID's Wocket Biometric Smart Wallet to Air on "I Want That" International CES Special 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
(Date:4/23/2015)... 23, 2015 Six startups from ... April 4-17 as part of the U.S.-Russia Innovation ... group of biotechnology startups to participate in the ... (UNN) and the University of Maryland (UMD) signed ... their respective universities in the biomedical industry in ...
(Date:4/23/2015)... 2015  Cryoport, Inc. (OTCBB: CYRX) ("Company"), the ... the life sciences industry, today announced that the ... within the animal husbandry market by signing a ... the shipment of equine semen for artificial insemination ... Animal husbandry is a multi-billion dollar ...
(Date:4/23/2015)... Irvine, CA (PRWEB) April 23, 2015 ... research leader in Personalized Medicine, is excited to ... Medication Response profile . This profile assesses 62 ... and provide dosing information for commonly prescribed non-opioid ... gabapentin (brand name Neurontin), alprazolam (brand name Xanax) ...
(Date:4/23/2015)... ReliantHeart's HeartAssist5® Ventricular Assist Device (VAD) ... the device) in real time, and this data is ... provider of Machine to Machine (M2M) communications for the ... VADLink.com can be monitored by a patient’s ... flow below a minimum threshold, the patient can be ...
Breaking Biology Technology:U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 2U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 3U.S.-Russian Innovation Corridor Program Connects Visiting Russian Startups to U.S. Experts 4Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 2Cryoport to Support the Equine Animal Husbandry Market Through Agreement with Yancey Farms 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3
Cached News: